Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 1
1968 2
1969 10
1970 1
1972 4
1974 4
1975 2
1978 1
1979 2
1980 2
1981 2
1982 1
1983 3
1984 2
1985 2
1986 1
1987 5
1988 4
1989 5
1990 8
1991 7
1992 4
1993 13
1994 6
1995 7
1996 12
1997 8
1998 11
1999 8
2000 12
2001 14
2002 19
2003 21
2004 21
2005 35
2006 26
2007 35
2008 39
2009 27
2010 29
2011 21
2012 27
2013 37
2014 59
2015 51
2016 59
2017 57
2018 65
2019 60
2020 80
2021 84
2022 71
2023 73
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

1,137 results

Results by year

Filters applied: . Clear all
Page 1
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.
Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, Offersen BV, Aznar MC, Belka C, Brunt AM, Dicuonzo S, Franco P, Krause M, MacKenzie M, Marinko T, Marrazzo L, Ratosa I, Scholten A, Senkus E, Stobart H, Poortmans P, Coles CE. Meattini I, et al. Lancet Oncol. 2022 Jan;23(1):e21-e31. doi: 10.1016/S1470-2045(21)00539-8. Lancet Oncol. 2022. PMID: 34973228 Review.
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.
Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, Alongi F, Ricardi U, Jereczek-Fossa BA, Westhoff P, But-Hadzic J, Widder J, Geets X, Bral S, Lambrecht M, Billiet C, Sirak I, Ramella S, Giovanni Battista I, Benavente S, Zapatero A, Romero F, Zilli T, Khanfir K, Hemmatazad H, de Bari B, Klass DN, Adnan S, Peulen H, Salinas Ramos J, Strijbos M, Popat S, Ost P, Guckenberger M. Kroeze SGC, et al. Lancet Oncol. 2023 Mar;24(3):e121-e132. doi: 10.1016/S1470-2045(22)00752-5. Lancet Oncol. 2023. PMID: 36858728 Review.
Radiotheranostics: a roadmap for future development.
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R. Herrmann K, et al. Lancet Oncol. 2020 Mar;21(3):e146-e156. doi: 10.1016/S1470-2045(19)30821-6. Lancet Oncol. 2020. PMID: 32135118 Free PMC article. Review.
Current Treatments in Marginal Zone Lymphoma.
Alderuccio JP, Kahl BS. Alderuccio JP, et al. Oncology (Williston Park). 2022 Apr 6;36(4):206-215. doi: 10.46883/2022.25920956. Oncology (Williston Park). 2022. PMID: 35436062 Free article. Review.
New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. Fortunati E, et al. Curr Treat Options Oncol. 2022 May;23(5):703-720. doi: 10.1007/s11864-022-00967-z. Epub 2022 Mar 24. Curr Treat Options Oncol. 2022. PMID: 35325412 Free PMC article. Review.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. Meattini I, et al. Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. Lancet Oncol. 2024. PMID: 38301705 Review.
Medical imaging and nuclear medicine: a Lancet Oncology Commission.
Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, Donoso-Bach L, Frija G, Hierath M, Holmberg O, Khong PL, Lewis JS, McGinty G, Oyen WJG, Shulman LN, Ward ZJ, Scott AM. Hricak H, et al. Lancet Oncol. 2021 Apr;22(4):e136-e172. doi: 10.1016/S1470-2045(20)30751-8. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676609 Free PMC article. Review.
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ. de Wild SR, et al. Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952707
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group. Saadatmand S, et al. Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17. Lancet Oncol. 2019. PMID: 31221620 Clinical Trial.
1,137 results